Developer docs
API playgroundTry for free, no card

Search company profiles

Avestria Ventures

Full company profile

uuid0003q6x

Namestring
Avestria Ventures
Legal namestring
Avestria Ventures Management, LLC
Websiteurl
avestria.vc
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Avestria Ventures is a San Francisco-based venture capital firm founded in 2019 by Harvard Business School classmates Linda Greub (Managing Partner) and Corinne Nevinny, focused exclusively on early-stage women's health and female-led life science companies. The firm defines women's health as conditions affecting women exclusively (menopause), differently (cardiovascular disease), or disproportionately (Alzheimer's), and seeks evidenced-based businesses using technology or data to improve healthcare quality, access, cost, or patient empowerment. Avestria manages two funds: Fund I closed in June 2021 with 13 portfolio companies and two exits (Alydia Health and Uqora, acquired by Pharmavite), and Fund II closed in July 2024 with nine portfolio companies including Axena Health, Clarified Precision Medicine, ENB Therapeutics, Elucent Medical, May Health, Meet Mae, Novocuff, AngioInsight, and Mercy BioAnalytics.

The firm operates with a lean core team of five (Managing Partner, Partner Tracy Dooley MD, Director of Marketing, Legal Counsel, Social Media Director) augmented by a network of 11 Avestria Advisors — medical doctors, scientists, and regulatory experts — plus LP Advisory Committees across funds. Its revenue model follows traditional VC economics: management fees and carried interest from limited partners, with no publicly disclosed fee rates or fund sizes. Avestria sources deals through direct outreach, founder referrals, and ecosystem partnerships, and markets itself via its website, quarterly newsletter, Women's Health Webinar series (launched 2023), and participation in industry conferences including the J.P. Morgan Healthcare Conference. The firm has been featured in Business Insider, Fast Company, Forbes, TechCrunch, NVCA, and Harvard Business School alumni media as a leading female-run VC investing in women's health.

The business is differentiated less by proprietary technology than by thematic focus, network curation, and founding-team operating credibility. Linda Greub's CFA plus life sciences operating experience (Applied Biosystems, VitaPath Genetics, Novartis Diagnostics, Singulex, Raindance) provides institutional-quality diligence infrastructure at emerging-manager scale. The investment thesis is anchored in a documented market gap — only 1% of healthcare VC funding historically flows to women's health companies per PitchBook, and 1.9% of VC went to female founders in 2022 — positioning Avestria as a specialist capturing what it characterizes as overlooked and undervalued opportunities.

Short descriptiontext

Avestria Ventures is a San Francisco-based venture capital firm founded in 2019 that invests seed and early-stage capital in women's health and female-led life science companies through two closed funds (Fund I 2021, Fund II 2024).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, women's health investing, life sciences funding, early-stage healthcare, female-led startups
Industry1 code
PRIMARYFSANAJAM
Gender Lens / Diversity, Equity & Inclusion (DEI) Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
NAICS code3 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
  • Funds, Trusts, and Other Financial Vehicles525
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeLicensing Royalties
Description

Avestria generates revenue through traditional VC fund management structures including management fees and carried interest from fund returns. Fund II was closed in July 2024 and Fund I was closed in June 2021.

avestria.vc
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Avestria Ventures is a venture capital firm that invests in early-stage women's health and female-led life science companies. The firm manages two funds — Fund I (closed June 2021) and Fund II (closed July 2024) — providing capital, strategic guidance, and access to a network of medical, scientific, and regulatory advisors to portfolio companies developing technology- and data-driven healthcare solutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Two successful exits from Fund I (Alydia Health and Uqora acquisition by Pharmavite)
+1 more record
Product overview1 text field

Avestria Ventures is a venture capital firm that operates two investment funds (Fund I, closed June 2021, and Fund II, closed July 2024) focused on seeding women's health and female-led life science ventures. The firm defines women's health as conditions affecting women exclusively, differently, or disproportionately. Avestria's portfolio companies include Midi Health (telehealth platform for midlife care), Raydiant Oximetry (fetal monitoring medical device), ViuHealth (real-world evidence platform), and Uqora (urinary health products, acquired by Pharmavite in 2021). The firm's investment strategy focuses on early-stage businesses utilizing technology and data to improve healthcare quality, access, cost, and patient empowerment.

Product and service2 records
1Avestria Ventures Fund II
CategoryInvestment fund
Description

A venture capital fund investing in early-stage women's health and female-led life science ventures. Portfolio includes Axena Health, Clarified Precision Medicine, ENB Therapeutics, Elucent Medical, May Health, Meet Mae, Novocuff, AngioInsight, and Mercy BioAnalytics.

2Avestria Ventures Fund I
CategoryInvestment fund
Description

A venture capital fund that invested in women's health and life science companies including Alydia Health (exited), AmplifiDx, Antiva Biosciences, AOA Dx, Avation Medical, Curio, Dahlia Biosciences, Genome Medical, Madorra, Midi Health, Raydiant Oximetry, and Uqora (exited).

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-17
Description

ViuHealth partners with The Leaders Rheum to transform rheumatology care, improving rheumatologists' ability to serve patients and increase virtual care capacity.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-03-24
Description

Partnered with DrugViu to help fill the gap in diverse patient data, develop diagnostics, and improve outcomes for minority patients with Inflammatory Bowel Disease.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Avestria's Managing Partner Linda Greub serves on Springboard Enterprises' Women's Health Executive Committee, supporting women-led companies in the healthcare sector.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment26 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avestria Ventures

Venture Capitalavestria.vc

Avestria Ventures is a San Francisco-based venture capital firm founded in 2019 that invests seed and early-stage capital in women's health and female-led life science companies through two closed funds (Fund I 2021, Fund II 2024).

What Avestria Ventures does

Avestria Ventures is a San Francisco-based venture capital firm founded in 2019 by Harvard Business School classmates Linda Greub (Managing Partner) and Corinne Nevinny, focused exclusively on early-stage women's health and female-led life science companies. The firm defines women's health as conditions affecting women exclusively (menopause), differently (cardiovascular disease), or disproportionately (Alzheimer's), and seeks evidenced-based businesses using technology or data to improve healthcare quality, access, cost, or patient empowerment. Avestria manages two funds: Fund I closed in June 2021 with 13 portfolio companies and two exits (Alydia Health and Uqora, acquired by Pharmavite), and Fund II closed in July 2024 with nine portfolio companies including Axena Health, Clarified Precision Medicine, ENB Therapeutics, Elucent Medical, May Health, Meet Mae, Novocuff, AngioInsight, and Mercy BioAnalytics.

The firm operates with a lean core team of five (Managing Partner, Partner Tracy Dooley MD, Director of Marketing, Legal Counsel, Social Media Director) augmented by a network of 11 Avestria Advisors — medical doctors, scientists, and regulatory experts — plus LP Advisory Committees across funds. Its revenue model follows traditional VC economics: management fees and carried interest from limited partners, with no publicly disclosed fee rates or fund sizes. Avestria sources deals through direct outreach, founder referrals, and ecosystem partnerships, and markets itself via its website, quarterly newsletter, Women's Health Webinar series (launched 2023), and participation in industry conferences including the J.P. Morgan Healthcare Conference. The firm has been featured in Business Insider, Fast Company, Forbes, TechCrunch, NVCA, and Harvard Business School alumni media as a leading female-run VC investing in women's health.

The business is differentiated less by proprietary technology than by thematic focus, network curation, and founding-team operating credibility. Linda Greub's CFA plus life sciences operating experience (Applied Biosystems, VitaPath Genetics, Novartis Diagnostics, Singulex, Raindance) provides institutional-quality diligence infrastructure at emerging-manager scale. The investment thesis is anchored in a documented market gap — only 1% of healthcare VC funding historically flows to women's health companies per PitchBook, and 1.9% of VC went to female founders in 2022 — positioning Avestria as a specialist capturing what it characterizes as overlooked and undervalued opportunities.

Avestria Ventures firmographics

Firmographics
Name
Avestria Ventures
Legal name
Avestria Ventures Management, LLC
Website
https://avestria.vc
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Avestria Ventures is a San Francisco-based venture capital firm founded in 2019 that invests seed and early-stage capital in women's health and female-led life science companies through two closed funds (Fund I 2021, Fund II 2024).
Ownership category
akta.pro rank

Avestria Ventures industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Funds, Trusts, and Other Financial Vehicles (525)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAJAM
Gender Lens / Diversity, Equity & Inclusion (DEI) Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds

Keywords

  • Venture capital
  • Women's health investing
  • Life sciences funding
  • Early-stage healthcare
  • Female-led startups

Where Avestria Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Avestria Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Fund Management: Avestria generates revenue through traditional VC fund management structures including management fees and carried interest from fund returns. Fund II was closed in July 2024 and Fund I was closed in June 2021.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Avestria Ventures product offering

Product offering

Core offering

Avestria Ventures is a venture capital firm that invests in early-stage women's health and female-led life science companies. The firm manages two funds — Fund I (closed June 2021) and Fund II (closed July 2024) — providing capital, strategic guidance, and access to a network of medical, scientific, and regulatory advisors to portfolio companies developing technology- and data-driven healthcare solutions.

Product overview

Avestria Ventures is a venture capital firm that operates two investment funds (Fund I, closed June 2021, and Fund II, closed July 2024) focused on seeding women's health and female-led life science ventures. The firm defines women's health as conditions affecting women exclusively, differently, or disproportionately. Avestria's portfolio companies include Midi Health (telehealth platform for midlife care), Raydiant Oximetry (fetal monitoring medical device), ViuHealth (real-world evidence platform), and Uqora (urinary health products, acquired by Pharmavite in 2021). The firm's investment strategy focuses on early-stage businesses utilizing technology and data to improve healthcare quality, access, cost, and patient empowerment.

Differentiator

Problem solved

Functional benefit

Products and services

  • Avestria Ventures Fund II A venture capital fund investing in early-stage women's health and female-led life science ventures. Portfolio includes Axena Health, Clarified Precision Medicine, ENB Therapeutics, Elucent Medical, May Health, Meet Mae, Novocuff, AngioInsight, and Mercy BioAnalytics.
  • Avestria Ventures Fund I A venture capital fund that invested in women's health and life science companies including Alydia Health (exited), AmplifiDx, Antiva Biosciences, AOA Dx, Avation Medical, Curio, Dahlia Biosciences, Genome Medical, Madorra, Midi Health, Raydiant Oximetry, and Uqora (exited).

Quantifiable outcome

  • Two successful exits from Fund I (Alydia Health and Uqora acquisition by Pharmavite)
  • +1 more outcomes

Companies that use Avestria Ventures

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Avestria Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Avestria Ventures partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • The Leaders RheumcoreStrategic or Co-development Partner · 17 January 2024ViuHealth partners with The Leaders Rheum to transform rheumatology care, improving rheumatologists' ability to serve patients and increase virtual care capacity.
  • Coral GenomicsminorStrategic or Co-development Partner · 24 March 2021Partnered with DrugViu to help fill the gap in diverse patient data, develop diagnostics, and improve outcomes for minority patients with Inflammatory Bowel Disease.
  • Springboard EnterprisescoreStrategic or Co-development PartnerAvestria's Managing Partner Linda Greub serves on Springboard Enterprises' Women's Health Executive Committee, supporting women-led companies in the healthcare sector.

Scale indicators3 records

Recent moves8 records

Expansion highlights4 records

Avestria Ventures competitors and assessment

Company assessment

Market position

Strengths5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Avestria Ventures social profiles

Digital presence

Avestria Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avestria Ventures leadership team

Management profile

Number of profiles

Profiles6 records

Avestria Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avestria Ventures M&A and investment

M&A and investment

M&A

Investments26 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avestria Ventures

What does Avestria Ventures do?

Avestria Ventures is a venture capital firm that invests in early-stage women's health and female-led life science companies. The firm manages two funds — Fund I (closed June 2021) and Fund II (closed July 2024) — providing capital, strategic guidance, and access to a network of medical, scientific, and regulatory advisors to portfolio companies developing technology- and data-driven healthcare solutions.

Is Avestria Ventures a public or private company?

Avestria Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Avestria Ventures founded?

Avestria Ventures was founded in 2019. It employs 1 to 10 people.

Where is Avestria Ventures based?

Avestria Ventures is headquartered in San Francisco, United States, in the North America region.

How does Avestria Ventures make money?

One revenue line is on record: fund Management.

Does Avestria Ventures have an API?

No public API is recorded for Avestria Ventures.

What industry is Avestria Ventures in?

Avestria Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAJAM, Gender Lens / Diversity, Equity & Inclusion (DEI) Funds. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AvestriaAVESTRIA VENTURES-Midi HealthA company profile chronicles Midi Health, a virtual care clinic for women navigating perimenopause and menopause, founded and led by Joanna Strober. Midi has raised $100 million to date, including a $25M Series A led by GV and a $60M Series B led by Emerson Collective, and plans to hire 150 clinicians by year-end and serve a million women by 2029.BeBeezNotizie da SoftBank Vision Fund 2, G Squared, Tribe Capital, Sequoia, DCM, Graph Ventures, Siguler Guf, Avestria Ventures, Myelin, Mubadala, VNV Global, RDIFPicsart raised $130 million in a Series C funding round led by SoftBank Vision Fund 2, achieving a valuation exceeding $1 billion with over 150 million monthly active users. Simultaneously, several venture capital firms including Avestria Ventures, Myelin, and Mubadala are launching new funds or closing existing ones to target sectors like women's health, biotech, and global delivery services.FinSMEsAvestria Ventures Completes First Life Sciences Venture FundAvestria Ventures closed its first fund, Avestria Ventures Fund I, to new investors. The fund's portfolio company Alydia Health was acquired by Organon for up to $240M, and Uqora was acquired by Pharmavite for an undisclosed amount.HomepageFeatured Funders: Linda Greub & Corinne Nevinny, Avestria Ventures Co-foundersAvestria Ventures co-founders Linda Greub and Corinne Nevinny outlined their investment thesis for early-stage women’s health and female-founded life science ventures in the U.S. The firm typically invests $250,000 in initial rounds with follow-on reserves of $500,000, targeting companies that utilize technology or data to improve healthcare access and quality. They currently hold an eight-company portfolio including Alydia Health, Avation Medical, Madorra, Raydiant Oximetry, and Uqora.